Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads under the STAYFREE and CAREFREE brands, and tampons under the o.b. brand; wound care products comprising adhesive bandages under the BAND-AID brand and first aid products under the NEOSPORIN brand. The company's Pharmaceutical segment offers various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolic, and pulmonary hypertension diseases. Its Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; diabetes care products that include blood glucose monitoring; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:JNJ
CUSIP47816010
Phone732-524-0400
Debt
Debt-to-Equity Ratio0.47
Current Ratio1.65
Quick Ratio1.33
Price-To-Earnings
Trailing P/E Ratio18.75
Forward P/E Ratio16.82
P/E Growth1.99
Sales & Book Value
Annual Sales$76.45 billion
Price / Sales4.80
Cash Flow$10.0058 per share
Price / Cash13.68
Book Value$22.39 per share
Price / Book6.11
Profitability
EPS (Most Recent Fiscal Year)$7.30
Net Income$1.30 billion
Net Margins1.70%
Return on Equity32.79%
Return on Assets13.66%
Miscellaneous
Employees134,000
Outstanding Shares2,682,900,000
Market Cap$350.79 billion
Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions
What is Johnson & Johnson's stock symbol?
Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?
Johnson & Johnson declared a quarterly dividend on Monday, July 16th. Investors of record on Tuesday, August 28th will be given a dividend of $0.90 per share on Tuesday, September 11th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.63%. The ex-dividend date is Monday, August 27th. View Johnson & Johnson's Dividend History.
How were Johnson & Johnson's earnings last quarter?
Johnson & Johnson (NYSE:JNJ) announced its earnings results on Tuesday, July, 17th. The company reported $2.10 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.06 by $0.04. The firm had revenue of $20.83 billion for the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The company's revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.83 earnings per share. View Johnson & Johnson's Earnings History.
When is Johnson & Johnson's next earnings date?
What guidance has Johnson & Johnson issued on next quarter's earnings?
Johnson & Johnson updated its FY18 earnings guidance on Tuesday, July, 17th. The company provided earnings per share guidance of $8.07-8.17 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.12. The company issued revenue guidance of $80.5-81.3 billion, compared to the consensus revenue estimate of $81.37 billion.
What price target have analysts set for JNJ?
19 analysts have issued 1-year target prices for Johnson & Johnson's stock. Their forecasts range from $110.00 to $165.00. On average, they anticipate Johnson & Johnson's share price to reach $143.2353 in the next year. This suggests a possible upside of 4.6% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.
What is the consensus analysts' recommendation for Johnson & Johnson?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 1 sell rating, 8 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Johnson & Johnson.
What are Wall Street analysts saying about Johnson & Johnson stock?
Here are some recent quotes from research analysts about Johnson & Johnson stock:
- 1. According to Zacks Investment Research, "J&J’s sales growth accelerated in the second half of 2017 backed by higher sales in the Pharmaceutical segment and improving performance in Medical Devices. Though quite a few key products in J&J’s portfolio like Remicade and Concerta are facing generic competition, we believe that new products in all segments, label expansion of drugs like Imbruvica and Darzalex and contribution from recent acquisitions - mainly Actelion – can support top-line growth. Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. However, headwinds like generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern. J&J’s shares have underformed the industry in this year so far. Estimates have risen slightly ahead of Q1 results. J&J has a positive record of earnings surprises in the recent quarters." (4/16/2018)
- 2. BTIG Research analysts commented, "Present – Starting to Outweigh Macro Tailwinds On Tuesday before market-open, JNJ reported 4Q17 financial results. In- line with our forecasting for the Pharma segment, the Actelion portfolio has begun to significantly disappoint expectations, Remicade erosion is accelerating, and mainstay franchises such as Imbruvica are beginning to moderate growth. The major discussion point we have had with investors is whether our negative Pharma thesis can trump the positive macro factors. We continue to think so, despite tailwinds such as tax reform helping the stock and overall stock market during 2H2017. At the end of the day, Pharma drives over 50% of total profit generation for the company. We reiterate our Sell rating and $110 PT. We forecast 1Q18 as the peak of recent Pharma growth and expect a mirror image of 2017 for the remainder of the year, whereby growth will moderate significantly into 2H2018: Our forecast calls for Pharma operational growth of +9.2%/ 6.3%/ 5.1%/ 4.3% during 1Q – 4Q2018, and we now explicitly include the approval of apalutamide within our forecasts (drug model inside report). Remicade erosion starting to become impactful and deteriorating pricing is likely affecting overall company gross margins: Mgmt noted that volumes for Remicade were generally steady during 4Q17, but this has come at the expense of pricing declines, which is a pure hit to product margins. Our best estimate is that the price erosion of Remicade negatively impacted overall company gross margins by – 30bps YoY during 4Q17." (1/24/2018)
Who are some of Johnson & Johnson's key competitors?
Some companies that are related to Johnson & Johnson include Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).
Who are Johnson & Johnson's key executives?
Johnson & Johnson's management team includes the folowing people:
- Mr. Alex Gorsky, Chairman & CEO (Age 58)
- Dr. Paulus A. Stoffels, Vice Chairman of Exec. Committee, Exec. VP & Chief Scientific Officer (Age 56)
- Mr. Joaquin Duato, Vice Chairman of Exec. Committee, Exec. VP & Worldwide Chairman of Pharmaceuticals (Age 55)
- Ms. Sandra E. Peterson, Exec. VP & Group Worldwide Chairman (Age 59)
- Mr. Joseph J. Wolk CPA, Exec. VP, CFO & Member of the Exec. Committee
Has Johnson & Johnson been receiving favorable news coverage?
Media stories about JNJ stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Johnson & Johnson earned a news and rumor sentiment score of 0.11 on Accern's scale. They also gave news coverage about the company an impact score of 45.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Johnson & Johnson.
Who are Johnson & Johnson's major shareholders?
Johnson & Johnson's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.65%), Phocas Financial Corp. (4.83%), Bank of New York Mellon Corp (1.25%), Massachusetts Financial Services Co. MA (1.13%), Glenmede Trust Co. NA (0.83%) and Morgan Stanley (0.80%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso and Paulus Stoffels. View Institutional Ownership Trends for Johnson & Johnson.
Which institutional investors are selling Johnson & Johnson stock?
JNJ stock was sold by a variety of institutional investors in the last quarter, including Dynasty Wealth Management LLC, Canada Pension Plan Investment Board, Russell Investments Group Ltd., FMR LLC, Bristol John W & Co. Inc. NY, Legal & General Group Plc, Teacher Retirement System of Texas and American Century Companies Inc.. View Insider Buying and Selling for Johnson & Johnson.
Which institutional investors are buying Johnson & Johnson stock?
JNJ stock was bought by a variety of institutional investors in the last quarter, including Phocas Financial Corp., Glenmede Trust Co. NA, Charles Schwab Investment Advisory Inc., BlackRock Inc., Cornerstone Wealth Management LLC, Renaissance Technologies LLC, Bank of Montreal Can and Flossbach Von Storch AG. View Insider Buying and Selling for Johnson & Johnson.
How do I buy shares of Johnson & Johnson?
Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Johnson & Johnson's stock price today?
One share of JNJ stock can currently be purchased for approximately $136.88.
How big of a company is Johnson & Johnson?
Johnson & Johnson has a market capitalization of $350.79 billion and generates $76.45 billion in revenue each year. The company earns $1.30 billion in net income (profit) each year or $7.30 on an earnings per share basis. Johnson & Johnson employs 134,000 workers across the globe.
How can I contact Johnson & Johnson?
Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.
MarketBeat Community Rating for Johnson & Johnson (NYSE JNJ)
MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe JNJ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNJ will underperform the S&P 500 over the long term. You may vote once every thirty days.
